Bayesian adaptive design for targeted therapy development in lung cancer - A step toward personalized medicine

Clinical Trials

Volumn 5, Issue 3, 2008, Pages 181-193

  Zhou, Xian ^a,b   Liu, Suyu ^a   Kim, Edward S ^a   Herbst, Roy S ^a   Lee, J Jack J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEXAROTENE; BIOLOGICAL MARKER; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN; RETINOID X RECEPTOR; SORAFENIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; TUMOR MARKER;

ARTICLE; BAYES THEOREM; CANCER THERAPY; DRUG EFFICACY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; INFORMATION STORAGE; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METHODOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; TREATMENT OUTCOME; BIOASSAY; COMPUTER SIMULATION; LUNG TUMOR; METABOLISM; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE;

BAYES THEOREM; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER SIMULATION; ENDPOINT DETERMINATION; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE; TUMOR MARKERS, BIOLOGICAL;

EID: 52649154223     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774508091815     Document Type: Article

References (40)

1. Palmer CR Ethics, data-dependent designs, and the strategy of clinical trials: Time to start learning-as-we-go? Statistical Methods in Medical Research 2002; 11: 381-402.
2. Thall PF Ethical issues in oncology biostatistics. Statistical Methods in Medical Research 2002; 11: 429-48.
3. Rosenberger WF Randomized play-the-winner clinical trials: Review and recommendations. Controlled Clinical Trials 1999; 20: 328-42.
4. Biswas A. Adaptive designs for binary treatment responses in phase III clinical trials: Controversies and progress. Statistical Methods in Medical Research 2001; 10: 353-64.
5. Rosenberger WF, Lachin JM Randomization in Clinical Trials: Theory and Practice. New York: Wiley, 2002.
6. Hu F., Rosenberger WF The Theory of Response-adaptive Randomization in Clinical Trials. Wiley, Hoboken, New Jersey, 2006.
7. Show S. -C, Chang M. Adaptive Design Methods in Clinical Trials. Chapman and Hall/CRC, Boca Raton, Florida, 2007.
8. Chang M. Adaptive Design Theory and Implementation Using SAS and R Chapman and Hall/CRC, Boca Raton, Florida, 2008.
9. Goodman SN Introduction to Bayesian methods I: Measuring the strength of evidence. Clinical Trials 2005; 2: 282-90.
10. Louis TA Introduction to Bayesian methods II: Fundamental concepts. Clinical Trials. 2005; 2: 291-94.
11. Berry DA Introduction to Bayesian methods III: Use and interpretation of Bayesian tools in design and analysis. Clinical Trials 2005; 2: 295-300.
12. Spiegelhalter DJ, Abrams KR, Myles JP Bayesian Approaches to Clinical Trials and Health-Care Evaluation. John Wiley & Sons, Chichester, West Sussex, UK, 2004.
13. Berry DA Bayesian statistics and the efficiency and ethics of clinical trials. Statistical Science. 2004; 19: 175-87.
14. Berry DA A guid to drug discovery: Bayesian clinical trials. Nature Reviews Drug Discovery 2006; 5: 27-36.
15. Berry DA Statistical innovations in cancer research. In Holland J, Frei T. et al. eds. Cancer Medicine. 7th edn. BC Decker, London, 2005; pp. 411-25.
16. Berry DA Adaptive trial design. Clinical Advances in Hematologic Oncology 2007; 5(7): 522-24.
17. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-15.
18. Scott NW, McPherson GC, Ramsay CR, Campbell MK The method of minimization for allocation to clinical trials. a review. Control Clin Trials 2002; 23: 662-74.
19. Thall PF, Wathen JK Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Statistics in Medicine. 2005; 24: 1947-64.
20. Park JW, Kerbel RS, Kelloff GJ, et al Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clinical Cancer Research 2004; 10: 3885-96.
21. Therasse P., Carbonnelle S., Bogaerts J. Clinical trials design and treatment tailoring: General principles applied to breast cancer research. Critical Reviews in Oncology/Hematology. 2006; 59: 98-105.
22. Carr KM, Rosenblatt K., Petricoin EF, Liotta LA Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy. Human Genomics 2004; 1: 134-40.
23. Kummar S., Gutierrez M., Doroshow JH, Murgo AJ Drug development in oncology: Classical cytotoxics and molecularly targeted agents. British Journal of Clinical Pharmacology 2006; 62: 15-26.
24. Markman M. Unique issues in the development of 'targeted' antineoplastic pharmaceutical agents. Current Oncology Reports 2005; 7: 235-36.
25. Chen EX, Siu LL Development of molecular targeted anticancer agents: Successes, failures and future directions. Current Pharmaceutical Design 2005; 11: 265-72.
26. Wolf M., Swaisland H., Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacy. Clinical Cancer Research. 2004; 10: 4607-13.
27. Fossella FV, DeVore R., Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. TAX 320 Non-Small-Cell Lung Cancer Study Group. Journal of Clinical Oncology 2000; 18: 2354-62.
28. Hanna N., Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97.
29. Lara Jr, PN, Redman MW, Kelly K., Gandara DR, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from Southwest Oncology Group randomized trials. Journal of Clinical Oncology 2008; 26: 463-67.
30. Albert JH, Chib S. Bayesian analysis of binary and polychotomous response Data. Journal of the American Statistical Association 1993; 88: 669-79.
31. Johnson VE, Albert JH Ordinal Data Modeling. Springer-Verlag, New York, 2000.
32. Pocock SJ Clinical Trials: A Practical Approach. Wiley, Chichester, 1983.
33. Friedman LM, Furberg C., DeMets DL Fundamentals of Clinical Trials. New York: Springer, 1998.
34. Piantadosi S. Clinical trials: A Methodologic Perspective. 2nd edn. Wiley-Interscience, Hoboken, 2005.
35. Lee, JJ Clinical Trial Design for Anticancer Therapies In Alison M, ed. The Cancer Handbook. John Wiley & Sons, Chichester, West Sussex, UK, 2nd edn 2007.
36. Simon R., Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research 2004; 10: 6759-63.
37. Maitournam A., Simon R. On the efficiency of targeted clinical trials. Statistics in Medicine. 2005; 24: 329-39.
38. Hu F., Rosenberger WF Optimality, Variability, Power: Evaluating Response-Adaptive Randomization Procedures for Treatment Comparisons. Journal of the American Statistical Association. 2003; 98: 671-78.
39. Coad DS, Ivanova A. Bias calculations for adaptive urn designs. Sequential Analysis. 2001; 20: 91-116.
40. Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. Journal of Clinical Oncology. 2005; 23: 4450-57.